4D Molecular Therapeutics, Inc. (FDMT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.80-8.86%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge 4D Molecular Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	5.17M
EPS	—	-1.062
Annual ending 2026-12-31
Revenue	—	13.26M
EPS	—	-4.151
Annual ending 2027-12-31
Revenue	—	18.34M
EPS	—	-4.094

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Strong cash and liquidity to fund operations	It has a strong cash position of about $514 million to fund development.	Intact	cash falls below $300 million	Cash and cash equivalents: $70.372M FY2026-Q2; GAAP. Published target: Maintain cash above $400 million. Target period is not explicitly aligned with this observation. Source date unavailable70,372,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improvement in financial results and earnings beats	The company beat earnings twice recently, showing improving financial performance.	Intact	EPS worsens or losses deepen beyond -$4 per share	Diluted EPS: $-1.04 per share FY2026-Q2; GAAP. Published target: earnings losses narrowing, EPS trending less negative. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-1.04 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 528e331d-871c-42e3-a5a8-2ff03c0630df. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth to sustain recovery	A primary condition in 4D Molecular Therapeutics, Inc.'s published investment case. The stated target is >= $85 million annual revenue.	Under Pressure	annual revenue falls below $50 million	Revenue: $3.781M FY2026-Q2; GAAP. Published target: >= $85 million annual revenue. The stored target says 2025-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 13, 20263,781,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 528e331d-871c-42e3-a5a8-2ff03c0630df. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.09

$-4.08 → $-4.09 · observed estimates

FY2027 revenue$0.02B

Unavailable → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.08	Unavailable	5 / 4
2026-07-25	$-4.08	Unavailable	5 / 4
2026-07-26	$-4.08	Unavailable	5 / 4
2026-07-27	$-3.77	$17,508,670	8 / 6
2026-07-28	$-4.08	Unavailable	5 / 4
2026-07-29	$-4.08	Unavailable	5 / 4
2026-07-30	$-3.77	$17,508,670	8 / 6
2026-07-31	$-3.77	$17,508,670	8 / 6
2026-08-01	$-4.08	Unavailable	5 / 4
2026-08-02	$-3.83	$17,616,860	9 / 7
2026-08-03	$-3.83	$17,616,860	9 / 7
2026-08-04	$-4.11	$17,466,583	6 / 5
2026-08-05	$-3.83	$17,616,860	9 / 7
2026-08-06	$-3.83	$17,616,860	9 / 7
2026-08-07	$-4.11	$17,466,583	6 / 5
2026-08-08	$-3.83	$17,616,860	9 / 7
2026-08-09	$-3.83	$17,616,860	9 / 7
2026-08-10	$-4.11	$17,466,583	6 / 5
2026-08-11	$-3.83	$17,616,860	9 / 7
2026-08-12	$-4.11	$17,466,583	6 / 5
2026-08-13	$-4.11	$17,466,583	6 / 5
2026-08-14	$-4.11	$17,466,583	6 / 5
2026-08-15	$-4.11	$17,466,583	6 / 5
2026-08-16	$-4.11	$17,466,583	6 / 5
2026-08-17	$-4.11	$17,466,583	6 / 5
2026-08-18	$-4.11	Unavailable	6 / 4
2026-08-19	$-4.11	$17,466,583	6 / 5
2026-08-20	$-4.09	$18,340,741	6 / 5
2026-08-21	$-4.09	$18,340,741	6 / 5
2026-08-22	$-4.09	$18,340,741	6 / 5
2026-08-23	$-4.09	$18,340,741	6 / 5
2026-08-24	$-4.09	$18,340,741	6 / 5
2026-08-25	$-4.09	$18,340,741	6 / 5
2026-08-26	$-4.09	$18,340,741	6 / 5
2026-08-27	$-4.09	$18,340,741	6 / 5
2026-08-28	$-4.09	$18,340,741	6 / 5
2026-08-29	$-4.09	$18,340,741	6 / 5
2026-08-30	$-4.09	$18,340,741	6 / 5
2026-08-31	$-4.09	$18,340,741	6 / 5
2026-09-01	$-4.09	$18,340,741	6 / 5
2026-09-02	$-4.09	$18,340,741	6 / 5
2026-09-03	$-4.09	$18,340,741	6 / 5
2026-09-04	$-4.09	$18,340,741	6 / 5
2026-09-05	$-4.09	$18,340,741	6 / 5
2026-09-06	$-4.09	$18,340,741	6 / 5
2026-09-07	$-4.09	$18,340,741	6 / 5
2026-09-08	$-4.09	$18,340,741	6 / 5
2026-09-09	$-4.09	$18,340,741	6 / 5
2026-09-10	$-4.09	$18,340,741	6 / 5
2026-09-11	$-4.09	$18,340,741	6 / 5
2026-09-12	$-4.08	$18,340,741	6 / 5
2026-09-13	$-4.08	$18,340,741	6 / 5
2026-09-14	$-4.08	$18,340,741	7 / 5
2026-09-15	$-4.09	$18,340,741	7 / 5
2026-09-16	$-4.09	$18,340,741	7 / 5
2026-09-17	$-4.09	$18,340,741	7 / 5
2026-09-18	$-4.09	$18,340,741	7 / 5
2026-09-19	$-4.09	$18,340,741	7 / 5
2026-09-20	$-4.09	$18,340,741	7 / 5
2026-09-21	$-4.09	$18,340,741	7 / 5
2026-09-22	$-4.09	$18,340,741	7 / 5
2026-09-23	$-4.09	$18,340,741	7 / 5
2026-09-24	$-4.09	$18,340,741	7 / 5
2026-09-25	$-4.09	$18,340,741	7 / 5
2026-09-26	$-4.09	$18,340,741	7 / 5
2026-09-27	$-4.09	$18,340,741	7 / 5
2026-09-28	$-4.09	$18,340,741	7 / 5
2026-09-29	$-4.09	$18,340,741	7 / 6
2026-09-30	$-4.09	$18,340,741	7 / 6
2026-10-01	$-4.09	$18,340,741	7 / 6
2026-10-02	$-4.09	$18,340,741	7 / 6
2026-10-03	$-4.09	$18,340,741	7 / 6
2026-10-04	$-4.09	$18,340,741	7 / 6
2026-10-05	$-4.09	$18,340,741	7 / 6
2026-10-06	$-4.09	$18,340,741	7 / 6
2026-10-07	$-4.09	$18,340,741	7 / 6
2026-10-08	$-4.09	$18,340,741	7 / 6
2026-10-09	$-4.09	$18,340,741	7 / 6
2026-10-10	$-4.09	$18,340,741	7 / 6
2026-10-11	$-4.09	$18,340,741	7 / 6
2026-10-12	$-4.09	$18,340,741	7 / 6
2026-10-13	$-4.09	$18,340,741	7 / 6
2026-10-14	$-4.09	$18,340,741	7 / 6
2026-10-15	$-4.09	$18,340,741	7 / 6
2026-10-16	$-4.09	$18,340,741	7 / 6
2026-10-17	$-4.09	$18,340,741	7 / 6
2026-10-18	$-4.09	$18,340,741	7 / 6
2026-10-19	$-4.09	$18,340,741	7 / 6
2026-10-20	$-4.09	$18,340,741	7 / 6
2026-10-21	$-4.09	$18,340,741	7 / 6
2026-10-22	$-4.09	$18,340,741	7 / 6
2026-10-23	$-4.09	$18,336,963	7 / 6
2026-10-24	$-4.09	$18,336,963	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	2
2026-06-01	9	2
2026-07-01	10	2
2026-08-01	10	2
2026-09-01	11	2
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

B.Riley FinancialOct 1

$37.00New observation · no comparable prior

$0$20.35$40.70

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Strong cash and liquidity to fund operationsCash and cash equivalents: $70.372M
Improvement in financial results and earnings beatsDiluted EPS: $-1.04 per share
Revenue growth to sustain recoveryPublished status: Under Pressure

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-41.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

4D Molecular Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

FDMT is a speculative clinical-stage biotechnology company, with its long-term thesis tied to developing treatments rather than established profits. The thesis is in watch mode: trial milestones are progressing, but earnings quality is weak, management execution has been described as volatile, and overall risk is elevated.

What's priced into 4D Molecular Therapeutics, Inc.

FDMT is expensive versus peers, with valuation supported in part by potential future clinical opportunity, or optionality. The valuation model has low confidence, and the evidence says the expensive valuation is not accompanied by a broader stack of fragility factors. The snapshot does not specify which clinical outcomes or expectations are already reflected in valuation.

What the fundamentals likely do

Near term, results may remain hard to assess because the company is loss-making and recent performance is neutral, with an earnings beat reported in August. Management is on track with 4D-150 trial milestones and reported positive two-year PRISM data with no new safety issues; topline Phase 3 data are expected in 2027. Cash and marketable securities declined between the first and second quarters of 2026, though management says they support operations into the second half of 2028; litigation filings and the risk of a guidance cut remain concerns.

What 4D Molecular Therapeutics, Inc. hinges on

The multi-year thesis depends on Phase 3 progress in wet AMD and DME, and whether future clinical data support the treatment’s potential and safety profile. A guidance cut would be a negative near-term signal, while worsening employment data could raise recession concerns across cyclical names. Continued strong results and guidance from large Healthcare companies could support sector momentum, but would not establish FDMT’s clinical outcomes.